StockNews.AI
VTRS
StockNews.AI
100 days

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - VTRS

1. Faruqi & Faruqi initiates investigation on Viatris's stock losses. 2. Viatris missed earnings estimates and offered lower 2025 guidance. 3. FDA issued warnings affecting Viatris's manufacturing facility in India. 4. Viatris stock dropped 15.21% following financial report release. 5. Investors encouraged to contact legal counsel regarding significant losses.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The missed earnings and reduced guidance point to ongoing operational issues. Historical examples show that such financial misses often lead to prolonged negative sentiment.

How important is it?

The article discusses major legal and financial issues affecting VTRS, crucial for investor sentiment.

Why Short Term?

Immediate market reaction to earnings can affect stock price short-term. However, potential improvements post-remediation could alter sentiment later.

Related Companies

VTRSPFEBMYMRKJNJ
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options If you suffered significant losses in Viatris stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 11, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On February 27, 2025, Viatris issued a press release reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics. In addition, Viatris provided lower-than-expected full-year guidance for 2025. Viatris also provided an update on remediation work at a manufacturing facility in India following receipt of a warning letter and import alert from the U.S. Food and Drug Administration, advising that it was "more than halfway through its remediation efforts and expects to be completed in a few months at which time the Company anticipates requesting FDA to conduct a reinspection of the facility."  On this news, Viatris's stock price fell $1.71 per share, or 15.21%, to close at $9.53 per share on February 27, 2025. To learn more about the Viatris Inc. investigation, go to www.faruqilaw.com/VTRS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c47d3945-81b3-40c2-9696-b30c6d4f0f1d

Related News